270 related articles for article (PubMed ID: 27984642)
21. Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.
Hiller JK; Schmoor C; Gaidzik VI; Schmidt-Salzmann C; Yalcin A; Abdelkarim M; Blagitko-Dorfs N; Döhner K; Bullinger L; Duyster J; Lübbert M; Hackanson B
Ann Hematol; 2017 Apr; 96(4):559-565. PubMed ID: 28058491
[TBL] [Abstract][Full Text] [Related]
22. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the
Ades L; Prebet T; Stamatoullas A; Recher C; Guieze R; Raffoux E; Bouabdallah K; Hunault M; Wattel E; Stalnikiewicz L; Toma A; Dombret H; Vey N; Sebert M; Gardin C; Chaffaut C; Chevret S; Fenaux P
Haematologica; 2017 Apr; 102(4):728-735. PubMed ID: 28034993
[TBL] [Abstract][Full Text] [Related]
23. The World Health Organisation classification of myelodysplastic syndromes contains prognostically relevant information beyond the prognostic scores IPSS-R or WPSS.
Metze K; Reis-Alves SC; Lorand-Metze I
Eur J Cancer; 2017 Feb; 72():266-268. PubMed ID: 28063637
[No Abstract] [Full Text] [Related]
24. Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights.
Shahrabi S; Khosravi A; Shahjahani M; Rahim F; Saki N
Oncol Rev; 2016 Oct; 10(2):311. PubMed ID: 28058097
[TBL] [Abstract][Full Text] [Related]
25. The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders.
Bejar R; Greenberg PL
J Natl Compr Canc Netw; 2017 Jan; 15(1):131-135. PubMed ID: 28040723
[No Abstract] [Full Text] [Related]
26. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Greenberg PL; Stone RM; Al-Kali A; Barta SK; Bejar R; Bennett JM; Carraway H; De Castro CM; Deeg HJ; DeZern AE; Fathi AT; Frankfurt O; Gaensler K; Garcia-Manero G; Griffiths EA; Head D; Horsfall R; Johnson RA; Juckett M; Klimek VM; Komrokji R; Kujawski LA; Maness LJ; O'Donnell MR; Pollyea DA; Shami PJ; Stein BL; Walker AR; Westervelt P; Zeidan A; Shead DA; Smith C
J Natl Compr Canc Netw; 2017 Jan; 15(1):60-87. PubMed ID: 28040720
[TBL] [Abstract][Full Text] [Related]
27. Total coumarins of Hedyotis diffusa induces apoptosis of myelodysplastic syndrome SKM-1 cells by activation of caspases and inhibition of PI3K/Akt pathway proteins.
Jiang J; Wang B; Li J; Ye B; Lin S; Qian W; Shan L; Efferth T
J Ethnopharmacol; 2017 Jan; 196():253-260. PubMed ID: 27988397
[TBL] [Abstract][Full Text] [Related]
28. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
[TBL] [Abstract][Full Text] [Related]
29. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Stone RM; Mandrekar SJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Lo-Coco F; Klisovic RB; Wei A; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Larson RA; Döhner H
N Engl J Med; 2017 Aug; 377(5):454-464. PubMed ID: 28644114
[TBL] [Abstract][Full Text] [Related]
30. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.
Jabbour E; Strati P; Cabrero M; O'Brien S; Ravandi F; Bueso-Ramos C; Wei Q; Hu J; Abi Aad S; Short NJ; Dinardo C; Daver N; Kadia T; Wierda W; Wei Y; Colla S; Borthakur G; Cortes J; Estrov Z; Kantarjian H; Garcia-Manero G
Am J Hematol; 2017 Apr; 92(4):351-358. PubMed ID: 28076892
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic work-up of acute myeloid leukemia.
Weinberg OK; Sohani AR; Bhargava P; Nardi V
Am J Hematol; 2017 Mar; 92(3):317-321. PubMed ID: 28066929
[TBL] [Abstract][Full Text] [Related]
32. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
Balsat M; Renneville A; Thomas X; de Botton S; Caillot D; Marceau A; Lemasle E; Marolleau JP; Nibourel O; Berthon C; Raffoux E; Pigneux A; Rodriguez C; Vey N; Cayuela JM; Hayette S; Braun T; Coudé MM; Terre C; Celli-Lebras K; Dombret H; Preudhomme C; Boissel N
J Clin Oncol; 2017 Jan; 35(2):185-193. PubMed ID: 28056203
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes.
Navada SC; Silverman LR
Ther Adv Hematol; 2017 Jan; 8(1):21-27. PubMed ID: 28042456
[TBL] [Abstract][Full Text] [Related]
34. Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia.
Fischer M; Schnetzke U; Spies-Weisshart B; Walther M; Fleischmann M; Hilgendorf I; Hochhaus A; Scholl S
Haematologica; 2017 Apr; 102(4):e129-e131. PubMed ID: 28034991
[No Abstract] [Full Text] [Related]
35. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
Fathi AT; Wander SA; Blonquist TM; Brunner AM; Amrein PC; Supko J; Hermance NM; Manning AL; Sadrzadeh H; Ballen KK; Attar EC; Graubert TA; Hobbs G; Joseph C; Perry AM; Burke M; Silver R; Foster J; Bergeron M; Ramos AY; Som TT; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Chen YB
Haematologica; 2017 Apr; 102(4):719-727. PubMed ID: 28034990
[TBL] [Abstract][Full Text] [Related]
36. The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
Uchida T; Hagihara M; Hua J; Inoue M
Leuk Res; 2017 Feb; 53():35-38. PubMed ID: 28013105
[TBL] [Abstract][Full Text] [Related]
37. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.
Prokocimer M; Molchadsky A; Rotter V
Blood; 2017 Aug; 130(6):699-712. PubMed ID: 28607134
[TBL] [Abstract][Full Text] [Related]
38. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Amatangelo MD; Quek L; Shih A; Stein EM; Roshal M; David MD; Marteyn B; Farnoud NR; de Botton S; Bernard OA; Wu B; Yen KE; Tallman MS; Papaemmanuil E; Penard-Lacronique V; Thakurta A; Vyas P; Levine RL
Blood; 2017 Aug; 130(6):732-741. PubMed ID: 28588019
[TBL] [Abstract][Full Text] [Related]
39. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
Zeidan AM; Hu X; Long JB; Wang R; Ma X; Podoltsev NA; Huntington SF; Gore SD; Davidoff AJ
Cancer; 2017 Oct; 123(19):3754-3762. PubMed ID: 28621841
[TBL] [Abstract][Full Text] [Related]
40. How I treat chronic myelomonocytic leukemia.
Solary E; Itzykson R
Blood; 2017 Jul; 130(2):126-136. PubMed ID: 28572287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
